Course Videos
What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?
Can you give us a specific example of a patient in which the failure to initially deploy, but then subsequent use of NGS-based, comprehensive molecular profiling led to documented improvements in their clinical course based on identification of targeted agent?
What did we learn from the SHIVA Trial and in what ways might the “disappointing” results of this trial have been misinterpreted, thereby underestimating the potential benefits of targeted therapy?
When exactly, in the course of a patient’s cancer diagnosis and history, does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for the purpose of identifying targeted therapies? And how do the capabilities of ...
What are the implications of the FDA having approved PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? And what are the implications for NGS-based molecular diagnostics?
What is the risk of not performing comprehensive NGS molecular profiling, and relying exclusively on more targeted panels? What might we miss?
Although you work in a tertiary cancer referral and research center where many patients have advanced disease, in general, at what point in the natural history of cancer do you think is the ideal time to perform NGS?
Can you share a case history of a patient who was failing multiple, standard therapies and then responded to treatment based on NGS profiling?
Can you give us patient-specific examples that demonstrate the potential clinical benefits — improvements in PFS, OS and other metrics — of whole exome, hybrid capture-based NGS?
How do you identify patients with targetable alterations that would suggest their triage into clinical trials?
How would you integrate all the currently available tests — NGS-based mutational profiles and burden and IHC biomarkers — to stratify patients into cohorts likely to be responsive to PD-1 checkpoint inhibitors?
Based on the evidence available, how should we be integrating and incorporating ctDNA profiling with tissue-based whole exome NGS, including longitudinal biopsies? In what settings, patients, and situations are these two tests potentially ...